What kind of treatment suits me? EuroEyes offers a full range of treatment procedures in the field of refractive surgeryRead more
Laser vision correction Correction of nearsightedness at the age from 18 to 45 years. ReLEx smile – gentle and safe procedure.Read more
Replacement of the lens Correction of presbyopia at the age from 45 years old: multifocal lenses. No more glasses!Read more
Innovations and advanced technologies Having introduced FEMTO-LASIK to Germany 15 years ago, EuroEyes is always focused on the next generation of technology: ReLEx smile, a minimally invasive laser eye surgery
Experienced Doctors Our surgeons expertise and excellence: FOCUS magazine 2016, Top doctors list recommends six EuroEyes doctors
Greetings from EuroEyes Denmark EuroEyes Denmark is located in Scandinavia directly north of Germany. Denmark has a population of roughly 6 million people – about the same size as the Hamburg region. What’s special about Denmark is the fact that EuroEyes Denmark has a close collaboration with a leading private hospital, Aleris-Hamlet, since the inception in 1993. EuroEyes functions as the refractive surgery centre of Aleris-Hamlet.More
Video: EuroEyes' Way to the Hong Kong Stock Exchange Accompany Dr. Jørgensen and his team with watching the video on their way to the Hong Kong Stock Exchange and find out how EuroEyes will help people in China.More
Thanks to Dr. Jørn Jørgensen and STAAR Surgical: A Life Without Glasses for Jannik Jørgensen Dr. Jørn Jørgensen, founder and CEO of EuroEyes, operates his own son with EVO Visian ICL lenses from Staar Surgical.More
EUROEYES SOARS 102% IN ITS HONG HONG IPO On 15th of October 2019, EuroEyes was successfully listed on the Main Board of The Stock Exchange of Hong Kong Limited. Morning trading volume almost equaled the shares sold by the German operator of eye clinics in the IPO, before the exercise of a greenshoe option, according to data compiled by Bloomberg. The stock pared some of the gains, up 59% in recent trading. EuroEyes raised $75.9 million selling shares last week at the midpoint of a marketed range.More